CIPROFLOXACIN TABLETS

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE)

Доступна с:

RANBAXY PHARMACEUTICALS CANADA INC.

код АТС:

J01MA02

ИНН (Международная Имя):

CIPROFLOXACIN

дозировка:

250MG

Фармацевтическая форма:

TABLET

состав:

CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 250MG

Администрация маршрут:

ORAL

Штук в упаковке:

100

Тип рецепта:

Prescription

Терапевтические области:

QUINOLONES

Обзор продуктов:

Active ingredient group (AIG) number: 0123207006; AHFS:

Статус Авторизация:

APPROVED

Дата Авторизация:

2009-08-20

Характеристики продукта

_ _
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
CIPROFLOXACIN TABLETS
Ciprofloxacin Tablets USP
250 MG, 500 MG, 750 MG CIPROFLOXACIN AS CIPROFLOXACIN HYDROCHLORIDE
ANTIBACTERIAL AGENT
Ranbaxy Pharmaceuticals Canada Inc.
126 East Drive
Brampton, Ontario
L6T 1C1
Date of Revision:
September 16, 2019
Submission Control No: 229183
_ _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................................3
SUMMARY PRODUCT INFORMATION
...................................................................................................3
INDICATIONS AND CLINICAL USE
.........................................................................................................3
CONTRAINDICATIONS
..............................................................................................................................7
WARNINGS AND PRECAUTIONS
............................................................................................................7
ADVERSE REACTIONS
............................................................................................................................
13
DRUG INTERACTIONS
.............................................................................................................................
17
DOSAGE AND ADMINISTRATION
.........................................................................................................
24
OVERDOSAGE
...........................................................................................................................................
27
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................................
27
STORAGE AND STABILITY
....................................................................................................................
29
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................................................
29
PART II: SCIENTIFIC INFORMATION
...........